Subcutaneous Saphnelo approved in EU

AstraZeneca’s Saphnelo (anifrolumab) was approved by the European Commission on Dec. 16, 2025 for subcutaneous self‑administration as a once‑weekly 120 mg pre‑filled pen for adults with moderate‑to‑severe, autoantibody‑positive systemic lupus erythematosus, based on a CHMP positive opinion and an interim positive Phase III TULIP‑SC readout showing a statistically significant reduction in disease activity versus placebo with a safety profile consistent with the IV formulation. The SC option—in a market where roughly 70% of biologic SLE patients in Europe use self‑administration—should expand patient access beyond clinic‑based infusions (Saphnelo IV is already approved in 70+ countries and used in >40,000 patients) and has potential to drive incremental uptake and sales if ongoing US and Japan reviews are successful. AstraZeneca will pay Bristol‑Myers Squibb a low‑to‑mid‑teens royalty on sales under the existing license agreement.

Analysis

AstraZeneca received European Commission approval on 16 December 2025 for subcutaneous self-administration of Saphnelo (anifrolumab) as a once‑weekly 120 mg pre‑filled pen for adults with moderate‑to‑severe, autoantibody‑positive systemic lupus erythematosus (SLE). The decision follows a positive CHMP opinion and an interim analysis from the Phase III TULIP‑SC trial where SC anifrolumab produced a statistically significant and clinically meaningful reduction in disease activity versus placebo at week 52 measured by BICLA, with a safety profile consistent with the established IV formulation.

Commercially, the SC approval addresses an existing European preference—AstraZeneca cites ~70% of biologic SLE patients in Europe use subcutaneous self‑administration—and should expand access beyond clinic infusions; Saphnelo IV is already approved in 70+ countries and >40,000 patients have been treated globally. Subcutaneous administration could accelerate uptake, reduce clinic burden and support guideline trends toward earlier biologic use and steroid minimisation that favour agents demonstrating remission or steroid‑sparing effects.

Key near‑term considerations include pending full TULIP‑SC publication and broader regulatory reviews in the US and Japan, and the commercial impact will be net of a low‑to‑mid‑teens royalty payable to Bristol‑Myers Squibb. Investors should track payer coverage, real‑world IV→SC conversion rates and long‑term safety/readthrough from the IV DORIS remission data to assess sustainable revenue growth.

Key Decisions for Investors

• Consider modestly increasing exposure to AstraZeneca (AZN) to reflect expanded European commercial optionality from a once‑weekly 120 mg subcutaneous Saphnelo that targets at‑home dosing and a population with established IV uptake (>40,000 treated),
• Monitor catalysts closely: full peer‑reviewed TULIP‑SC data, US and Japan regulatory outcomes, payer reimbursement decisions and real‑world uptake metrics including IV‑to‑SC conversion rates,
• Incorporate a low‑to‑mid‑teens royalty to Bristol‑Myers Squibb into incremental revenue models and consider hedging near‑term exposure until reimbursement visibility and sustained adoption are confirmed